Redeye revisits the Alzinova equity story with the initiation of clinical trials with ALZ-101, its vaccine candidate in Alzheimer’s, an indication with a vast unmet medical need. Now is the time when the case could start to heat up. ALZ-101 is a candidate that stands out in a clinical pipeline that is set to gain increasing attention, thus, we have reviewed our financial forecasts and present an updated fair value range.